HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ:CADL) with a Buy and maintains $23 price target.
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ:CADL) with a Buy and maintains $23 price target.